Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
about
Increasing options for the treatment of osteoporosisPatient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial.Evaluation of the osteogenic effect of low-level laser therapy (808 nm and 660 nm) on bone defects induced in the femurs of female rats submitted to ovariectomy.Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.Efficacy of ibandronate: a long term confirmation.Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice.A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational dataZoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massAppropriate use of anabolic treatment for severe osteoporosisPlacebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials.Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands.Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.A critical review of brand and generic alendronate for the treatment of osteoporosis.A cohort study of 4,190 patients treated with low-intensity pulsed ultrasound (LIPUS): findings in the elderly versus all patients.Measuring and improving adherence to osteoporosis pharmacotherapy.The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.The role of galenic innovation in improving treatment compliance and persistence: three case studies.Mechanical competence of ovariectomy-induced compromised bone after single or combined treatment with high-frequency loading and bisphosphonates.Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendationsBisphosphonate prescribing, persistence and cumulative exposure in Ontario, CanadaAdherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare populationPersistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional studyUpper gastrointestinal tract transit times of tablet and drinkable solution formulations of alendronate: a bioequivalence and a quantitative, randomized study using video deglutitionIn Vivo Study on the Pharmacological Interactions between a Chinese Herbal Formula ELP and Antiresorptive Drugs to Counteract OsteoporosisSecular trends in the incidence of hip and other osteoporotic fractures.Osteoporosis: now and the futureCost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence.Can Alarming Improve Compliance with Weekly Bisphosphonate in Patients with Osteoporosis?Which Bisphosphonate? It's the Compliance!: Decision Analysis.Association between gastrointestinal events and compliance with osteoporosis therapy.Premenopausal women with a distal radial fracture have deteriorated trabecular bone density and morphology compared with controls without a fractureAssociation between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research DatabaseOsteoporosis medication adherence: physician perceptions vs. patients' utilization.GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
P2860
Q28254516-9872B4E7-3F31-4C63-8EDB-9858FFA30634Q33746674-E016633E-1C2E-4E14-B736-26B0AAC51F37Q33796865-90051066-1DE1-4C96-8599-2D628BBC0B0BQ33841204-7442AFBF-C87D-4A44-A9EA-BB9A8CE90295Q33965657-E87C0472-6814-4917-BC5C-D7701E6ACEC5Q33966587-E35E0B57-B6E9-4167-9527-0C9CBE4E9E8DQ34016943-C850843A-A467-489B-9630-1BB17A51542DQ34316224-AB923FE4-16D5-4739-AEDB-4069DD63CAFBQ34389524-FACCDDA1-FC31-48D7-B4B1-0EC90ABECF91Q34417198-C5786681-4D7E-4138-B9EE-33440EA0188FQ34441060-53EE1495-2490-412F-AB29-3123CC728152Q34699332-655AC8D2-4E6D-44E6-9473-C554F54A71BAQ34774658-4910FD58-8121-44D4-B66C-F5CA849C123AQ34863304-F1932085-9966-41F2-9D9C-32BF6B772FB7Q35026446-6D409636-0AC9-429F-9431-073241E2AB42Q35050249-7E242F47-2F27-4FE0-97F2-E741FEE9F813Q35059218-A2A03385-48A5-4D8D-AA8D-AF4D6B14C49FQ35170047-F1650F2F-5335-4B13-A20F-26D6FCA9CD0AQ35177690-3AE3E7C2-B42D-429E-BB02-194DA794D4CEQ35230000-DB47E8B5-1BC8-4AC7-AF0D-A6D8020FBEA4Q35454381-BC659D69-0113-4704-AE22-0FE6A08CAD63Q35669754-16AB35B7-A82C-4CA2-9DC5-ADAF8510EE2CQ35693057-53D043FA-8B10-4ED4-BCEF-11073259C4EEQ35751437-4E5CCD97-E077-4AC1-8779-F6BC0F79F9A7Q35751984-39A626DB-9550-45AE-B2A2-A10DDB5AE79BQ35840753-24BAC569-A901-4853-A72D-5262CA3CF770Q35968876-3EFEE66A-DAAB-4EB6-A7A8-CEBC2EAAA399Q36073613-5457022F-3DE7-4A05-A36B-567232AE9EEDQ36303853-20737ABE-79DD-4998-8BE6-37D02C126E5DQ36369348-512B966C-839A-41BC-AD7E-F7D708B8B314Q36537168-B397B50C-E54D-4957-94DA-7CC1A2F2EA48Q36564425-994AF4AE-FEC7-446D-8D8E-12CD1F95AD66Q36763643-3C915BAF-560D-4AED-B1E0-121E0006D871Q36989616-93E07018-6FD5-46E8-8894-AFBDB27C33B9Q36989633-F9A197B5-07C4-438B-BE65-E0DB47FD0CB6Q37051660-E5666E1E-E88C-4E65-86CC-9322C710AAFBQ37109419-01CC3B44-5BA3-4E26-BAA4-3B021C390080Q37168515-E8EE2042-8D4F-4EEB-8236-B837D7F20C7CQ37183237-8096D65D-5294-4BDC-A42A-24592F91F664Q37298020-A0AFDF97-5D64-4724-8365-6EC63B9C7DE2
P2860
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
@en
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
@nl
type
label
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
@en
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
@nl
prefLabel
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
@en
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
@nl
P2093
P1476
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe
@en
P2093
Ethel S Siris
Fredrik Borgström
Kenneth G Saag
Ron M C Herings
Stuart L Silverman
P356
10.1016/J.AMJMED.2008.12.002
P407
P433
P50
P577
2009-02-01T00:00:00Z